Christine Lovly

Associate Professor of Medicine with Tenure

Vanderbilt University Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Christine Lovly is an Associate Professor of Medicine with Tenure at Vanderbilt University Medical Center in the United States. Her research focuses on precision oncology, particularly in lung cancer therapies, including targeted treatments for ALK+ and EGFR mutations. Recent publications highlight her work on overcoming drug resistance and improving treatment outcomes through advanced immunotherapy and genomic testing methodologies.

Articles (15)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2020

Year:

2020

Year:

2020

Year:

UNITED STATES

View details

Ian Donaldson

The University of Manchester

UNITED KINGDOM

View details

Allison Walker

Assistant Professor

Vanderbilt University

UNITED STATES

View details

Kaitlyn Ledwitch

Research Assistant Professor

Vanderbilt University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Christine Lovly

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics

Unlocking the Next Frontier in Precision Oncology: Addressing Drug-Tolerant Residual Disease

Refining neoadjuvant immunotherapy for resectable lung cancer.

New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses 5 years

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E

Perioperative Immunotherapy — A KEY toward Improved Outcomes for Early-Stage Lung Cancer?

Ferrying Oncologists Across the Chasm of Interpreting Biomarker Testing Reports: Systematic Support Needed to Improve Care and Decrease Disparities

Reply to J.M. Kolesar et al, J.S. Bates et al, and T.C. Knepper et al

SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors

Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion

N-[18F]-Fluoroacetylcrizotinib: A potentially potent and selective PET tracer for molecular imaging of non-small cell lung cancer.

Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition.

COVID-19 and immune checkpoint inhibitors: initial considerations.

Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance.

Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group.

Collaborators (11)

Bhuminder Singh

Debyani Chakravarty

Pamela Hershberger

Stacy Gray

Misty Shields

Benjamin Brown

Adam Smith

Vincent K. Lam

Ian Donaldson

Allison Walker

Kaitlyn Ledwitch

Make your next move.